Cullinan Therapeutics, Inc. CGEM 深 沪
等待开盘 10-16 09:30:00 美东时间
14.00
+0.360
+2.64%
华盛通- 最 高14.18
- 今 开13.62
- 成交量 97.21万股
- 最 低 13.455
- 昨 收 13.64
- 总市值 9.01亿
- 52周最高 23.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.7318
- 委 比 81.33%
- 总股本 6435.47万
- 历史最高 59.85
- 量 比 1.36
- 振 幅 5.32%
- 历史最低 5.68
- 每 手 1
- 风险率 3.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.
10-02 18:32
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
09-25 17:49
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026 Company to host a virtual event on Monday, September 14, 2026, at ...
09-11 01:03
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.
08-13 21:02
Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 07:40
Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 24.3 percent increase over losses of $(1.07) per share from the same period last year.
08-06 19:45
